Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7P3C

EED in complex with compound 4

Summary for 7P3C
Entry DOI10.2210/pdb7p3c/pdb
DescriptorPolycomb protein EED, N-(2,3-dihydro-1-benzofuran-4-ylmethyl)-8-(4-methylsulfonylphenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, N-[5-[(5-fluoranyl-2,3-dihydro-1-benzofuran-4-yl)methylamino]-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl]benzamide, ... (4 entities in total)
Functional Keywordsmethyl transferase eed prc2 epigenetic h3k27 wd40 inhibitor, protein binding
Biological sourceHomo sapiens (Human)
Total number of polymer chains2
Total formula weight85424.26
Authors
Read, J.A. (deposition date: 2021-07-07, release date: 2021-12-08, Last modification date: 2024-01-31)
Primary citationBagal, S.K.,Gregson, C.,O' Donovan, D.H.,Pike, K.G.,Bloecher, A.,Barton, P.,Borodovsky, A.,Code, E.,Fillery, S.M.,Hsu, J.H.,Kawatkar, S.P.,Li, C.,Longmire, D.,Nai, Y.,Nash, S.C.,Pike, A.,Robinson, J.,Read, J.A.,Rawlins, P.B.,Shen, M.,Tang, J.,Wang, P.,Woods, H.,Williamson, B.
Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
J.Med.Chem., 64:17146-17183, 2021
Cited by
PubMed Abstract: Aberrant activity of the histone methyltransferase polycomb repressive complex 2 (PRC2) has been linked to several cancers, with small-molecule inhibitors of the catalytic subunit of the PRC2 enhancer of zeste homologue 2 (EZH2) being recently approved for the treatment of epithelioid sarcoma (ES) and follicular lymphoma (FL). Compounds binding to the EED subunit of PRC2 have recently emerged as allosteric inhibitors of PRC2 methyltransferase activity. In contrast to orthosteric inhibitors that target EZH2, small molecules that bind to EED retain their efficacy in EZH2 inhibitor-resistant cell lines. In this paper we disclose the discovery of potent and orally bioavailable EED ligands with good solubilities. The solubility of the EED ligands was optimized through a variety of design tactics, with the resulting compounds exhibiting in vivo efficacy in EZH2-driven tumors.
PubMed: 34807608
DOI: 10.1021/acs.jmedchem.1c01161
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.61 Å)
Structure validation

229183

PDB entries from 2024-12-18

PDB statisticsPDBj update infoContact PDBjnumon